Moxifloxacin
- Generic Name
- Moxifloxacin
- Brand Names
- Avelox, Moxeza, Vigamox
- Drug Type
- Small Molecule
- Chemical Formula
- C21H24FN3O4
- CAS Number
- 151096-09-2
- Unique Ingredient Identifier
- U188XYD42P
- Background
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
- Indication
For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
- Associated Conditions
- Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections
Avelox for Treatment of Elderly Patients With Community Acquired Pneumonia
- Conditions
- Pneumonia
- Interventions
- First Posted Date
- 2008-04-23
- Last Posted Date
- 2014-11-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 401
- Registration Number
- NCT00665327
Moxifloxacin Versus Amoxicillin Clavulanic Acid in Treatment of Acute Exacerbation of Chronic Bronchitis
- Conditions
- Chronic Bronchitis
- Interventions
- First Posted Date
- 2008-04-11
- Last Posted Date
- 2014-12-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1372
- Registration Number
- NCT00656747
Moxifloxacin vs. Polytrim for Conjunctivitis
- First Posted Date
- 2007-12-27
- Last Posted Date
- 2016-01-18
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 124
- Registration Number
- NCT00581542
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States
A Phase II Study of Moxidex Ophthalmic Solution for Treatment of Marginal Corneal Infiltrates
- Conditions
- Corneal Infiltrates
- Interventions
- Drug: Moxifloxacin/dexamethasone phosphate ophthalmic solution
- First Posted Date
- 2007-12-21
- Last Posted Date
- 2012-12-05
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 144
- Registration Number
- NCT00579020
- Locations
- 🇺🇸
Contact Alcon Call Center at 1-888-451-3937, Fort Worth, Texas, United States
A Phase II Study of an Otic Formulation in Treating Peri-Operative Tube Otorrhea
- Conditions
- Acute Otitis Media
- Interventions
- First Posted Date
- 2007-12-21
- Last Posted Date
- 2012-12-03
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 303
- Registration Number
- NCT00578773
Phase III Study of an Otic Formulation in Acute Otitis Media With Tympanostomy Tubes
- Conditions
- Acute Otitis Media
- Interventions
- First Posted Date
- 2007-12-21
- Last Posted Date
- 2012-12-03
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 776
- Registration Number
- NCT00579189
Study of AzaSite Versus Vigamox in the Tears of Healthy Volunteers
- Conditions
- Bacterial InfectionsEye Infections
- Interventions
- First Posted Date
- 2007-12-18
- Last Posted Date
- 2011-09-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 37
- Registration Number
- NCT00575367
- Locations
- 🇺🇸
Mount Sinai School of Medicine, New York, New York, United States
Study of AzaSite Versus Vigamox Concentrations in the Conjunctiva and Aqueous Humor in Subjects Undergoing Routine Cataract Surgery
- Conditions
- Bacterial InfectionsEye InfectionsCataract Extraction
- Interventions
- First Posted Date
- 2007-12-18
- Last Posted Date
- 2011-09-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 116
- Registration Number
- NCT00575380
- Locations
- 🇺🇸
Eye Care Specialists, Kingston, Pennsylvania, United States
🇺🇸Ophthalmic Consultants of Long Island, Rockville Centre, New York, United States
🇺🇸Ophthalmology Associates, St. Louis, Missouri, United States
Study of AzaSite (Azithromycin) Versus Vigamox in the Conjunctiva of Healthy Volunteers
- Conditions
- Bacterial InfectionsEye Infections
- Interventions
- First Posted Date
- 2007-11-28
- Last Posted Date
- 2011-09-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 48
- Registration Number
- NCT00564447
Staccato Prochlorperazine Thorough QT/QTc
- Conditions
- Cardiotoxicity
- Interventions
- Drug: Inhaled placeboDrug: Oral placebo
- First Posted Date
- 2007-10-12
- Last Posted Date
- 2019-03-11
- Lead Sponsor
- Alexza Pharmaceuticals, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT00543062
- Locations
- 🇺🇸
Covance Clinical Research Unit Inc., Evansville, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.